Since 1975
  • facebook
  • twitter
  • instagram
  • Home
  • Fujifilm’s Avigan shown to be effective in Japanese Phase-3 trial for COVID-19

Fujifilm’s Avigan shown to be effective in Japanese Phase-3 trial for COVID-19

The government called on Fujifilm to triple national stockpiles of Avigan, approved in 2014 as an emergency flu treatment, and pledged to donate it to countries on request. (AFP)
The government called on Fujifilm to triple national stockpiles of Avigan, approved in 2014 as an emergency flu treatment, and pledged to donate it to countries on request. (AFP)
Short Url:
23 Sep 2020 01:09:41 GMT9
23 Sep 2020 01:09:41 GMT9

TOKYO: Fujifilm Holdings Corp said on Wednesday its Avigan drug reduced viral loads and symptoms of COVID-19 patients, paving the way for regulatory approval in Japan after months of delays.

The Phase 3 clinical study of 156 patients showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group. Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release.

Former Japanese Prime Minister Shinzo Abe had touted Avigan’s potential as Japan’s contribution to a global race for coronavirus treatments, aiming for domestic approval in May.

The government called on Fujifilm to triple national stockpiles of Avigan, approved in 2014 as an emergency flu treatment, and pledged to donate it to countries on request.

Fujifilm shares jumped 4.5% in Tokyo versus a 0.4% drop in the broader market. 

Reuters

Most Popular
Recommended

return to top